A Phase 2 interventional study of Setmelanotide in Genetic Obesity, Obesity and Obesity Due to Melanocortin 4 Receptor Deficiency, sponsored by Rhythm Pharmaceuticals, Inc.. Completed at 58 sites in 9 countries. Open to participants aged 6 Years and older. Per ClinicalTrials.gov, last updated 2023-08-18.
Sponsored by Rhythm Pharmaceuticals, Inc. · Phase 2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 16 studies testing setmelanotide in Obesity — 1 open to participants now, 2 under way, none of them phase 3. setmelanotide · Obesity.
Among the 16 studies testing setmelanotide in Obesity, this one is the 2nd largest by enrollment, is one of 3 that started in 2017, is one of 6 in phase 2, and was the 6th registered.
11,543 studies on the registry are indexed under Obesity; 2,042 are open to participants now.
Browse Obesity studies →1 of the 16 studies testing setmelanotide in Obesity is open now, in 1 country. Recruiting first, the newest first:
Massachusetts General Hospital · Sites in United States
By country, each count listing its studies:
setmelanotide: first FDA approval 2020 (IMCIVREE), first EMA approval 2021. What it is approved for, and how studies give it, is on its page →
Of the 1,339 Obesity studies recruiting now, 377 (28%) set no upper age limit and 859 (64%) stop at 75 or younger; 167 take children under 18; 490 take healthy volunteers.
This study: 6 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
16 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 3 · Phase 2 8 · Phase 3 7
First in 2012; this study’s year is marked. 3 started in 2017.
This study's enrollment of 213 is above the median of 67 across 9,016 interventional studies indexed under Obesity.
Median enrollment 34 across the 16 interventional studies. Of the 14 that completed or were terminated, 10 (71%) have results posted.
This tab as a report to print or save as PDF → With an account.
15 of 16 have an industry lead sponsor. The 2 most frequent:
Rhythm Pharmaceuticals, Inc. is the lead sponsor of 29 studies on the registry; 2 are open to participants now.
Of its 19 completed or terminated interventional studies of FDA-regulated products, 15 (79%) have results posted.
19 studies in Obesity by Rhythm Pharmaceuticals, Inc.: none open now, 2 under way, none of them phase 3. Of 16 finished, 10 (63%) have results posted.
Among the 19 studies in Obesity by Rhythm Pharmaceuticals, Inc., this one is the 2nd largest by enrollment of the 16 interventional ones that give a count, is one of 3 that started in 2017, is one of 5 in phase 2, and was the 6th registered.
Rhythm Pharmaceuticals, Inc.’s Obesity studies by the year they started, since 2012.
1 of the studies testing setmelanotide in Obesity that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07496463Massachusetts General HospitalSetmelanotide to Treat Obesity in a Patient With Pseudohypoparathyroidism Type 1a (PHP1a) | 2027-04-30 |
Add it to your calendar (.ics) → With an account.
Among the 16 studies testing setmelanotide in Obesity, from their registry updates:
Among Rhythm Pharmaceuticals, Inc.’s 19 in Obesity:
This tab as a report to print or save as PDF → With an account.
The purpose of the study was to determine the effect of setmelanotide (RM-493) on weight, hunger assessments, and other factors in participants with rare genetic disorders of obesity.
Inclusion Criteria:
Participants with the following genotypes and/or clinical assessment:
Key Exclusion Criteria:
Other protocol defined Inclusion/Exclusion criteria may apply.
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.
GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².
Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
BMI (body mass index)
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Childbearing potential
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HbA1c
A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
GFR and eGFR (kidney filtering)
GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².
Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Participants with chromosomal rearrangement of the p11.2 region of chromosome 16 (16p11.2) locus causing obesity received setmelanotide once daily (QD) via subcutaneous (SC) injection for 16 weeks. All participants initiated treatment with setmelanotide (starting dose being age dependent) and the dose was escalated up to a maximum dose of 3.0 mg QD. Participants either continued setmelanotide treatment by enrolling in an extension study (RM-493-022; NCT03651765) immediately following the last dose in this study or if the extension study was not open at the current clinic site, participants continued treatment in the current study for up to 1 year, resulting in treatment duration of up to 16 months.
Drug: Setmelanotide
Participants with Alström syndrome (AS) received setmelanotide QD via SC injection for 16 weeks. All participants initiated treatment with setmelanotide (starting dose being age dependent) and the dose was escalated up to a maximum dose of 3.0 mg QD. Participants either continued setmelanotide treatment by enrolling in an extension study (RM-493-022; NCT03651765) immediately following the last dose in this study or if the extension study was not open at the current clinic site, participants continued treatment in the current study for up to 1 year, resulting in treatment duration of up to 16 months.
Drug: Setmelanotide
Participants with Bardet-Biedl syndrome (BBS) received setmelanotide QD via SC injection for 16 weeks. All participants initiated treatment with setmelanotide (starting dose being age dependent) and the dose was escalated up to a maximum dose of 3.0 mg QD. Participants either continued setmelanotide treatment by enrolling in an extension study (RM-493-022; NCT03651765) immediately following the last dose in this study or if the extension study was not open at the current clinic site, participants continued treatment in the current study for up to 1 year, resulting in treatment duration of up to 16 months.
Drug: Setmelanotide
Participants with melanocortin-4 receptor (MC4R) deficiency obesity received setmelanotide QD via SC injection for 16 weeks. All participants initiated treatment with setmelanotide (starting dose being age dependent) and the dose was escalated up to a maximum dose of 3.0 mg QD. Participants either continued setmelanotide treatment by enrolling in an extension study (RM-493-022; NCT03651765) immediately following the last dose in this study or if the extension study was not open at the current clinic site, participants continued treatment in the current study for up to 1 year, resulting in treatment duration of up to 16 months.
Drug: Setmelanotide
Participants with pro-opiomelanocortin (POMC)/proprotein convertase subtilisin/kexin type 1 (PCSK1)/leptin receptor (LEPR) heterozygous mutations received setmelanotide QD via SC injection for 16 weeks. All participants initiated treatment with setmelanotide (starting dose being age dependent) and the dose was escalated up to a maximum dose of 3.0 mg QD. Participants either continued setmelanotide treatment by enrolling in an extension study (RM-493-022; NCT03651765) immediately following the last dose in this study or if the extension study was not open at the current clinic site, participants continued treatment in the current study for up to 1 year, resulting in treatment duration of up to 16 months.
Drug: Setmelanotide
Participants with POMC/PCSK1/LEPR composite heterozygous mutations received setmelanotide QD via SC injection for 16 weeks. All participants initiated treatment with setmelanotide (starting dose being age dependent) and the dose was escalated up to a maximum dose of 3.0 mg QD. Participants either continued setmelanotide treatment by enrolling in an extension study (RM-493-022; NCT03651765) immediately following the last dose in this study or if the extension study was not open at the current clinic site, participants continued treatment in the current study for up to 1 year, resulting in treatment duration of up to 16 months.
Drug: Setmelanotide
Participants with POMC/PCSK1/LEPR compound heterozygous mutations received setmelanotide QD via SC injection for 16 weeks. All participants initiated treatment with setmelanotide (starting dose being age dependent) and the dose was escalated up to a maximum dose of 3.0 mg QD. Participants either continued setmelanotide treatment by enrolling in an extension study (RM-493-022; NCT03651765) immediately following the last dose in this study or if the extension study was not open at the current clinic site, participants continued treatment in the current study for up to 1 year, resulting in treatment duration of up to 16 months.
Drug: Setmelanotide
Participants with steroid receptor coactivator (SRC) homology 2B adapter protein 1 (SH2B1) haploinsufficiency received setmelanotide QD via SC injection for 16 weeks. All participants initiated treatment with setmelanotide (starting dose being age dependent) and the dose was escalated up to a maximum dose of 3.0 mg QD. Participants either continued setmelanotide treatment by enrolling in an extension study (RM-493-022; NCT03651765) immediately following the last dose in this study or if the extension study was not open at the current clinic site, participants continued treatment in the current study for up to 1 year, resulting in treatment duration of up to 16 months.
Drug: Setmelanotide
Participants with Smith-Magenis Syndrome (SMS) received setmelanotide QD via SC injection for 16 weeks. All participants initiated treatment with setmelanotide (starting dose being age dependent) and the dose was escalated up to a maximum dose of 3.0 mg QD. Participants either continued setmelanotide treatment by enrolling in an extension study (RM-493-022; NCT03651765) immediately following the last dose in this study or if the extension study was not open at the current clinic site, participants continued treatment in the current study for up to 1 year, resulting in treatment duration of up to 16 months.
Drug: Setmelanotide
Participants with steroid receptor coactivator 1 (SRC1) mutations received setmelanotide QD via SC injection for 16 weeks. All participants initiated treatment with setmelanotide (starting dose being age dependent) and the dose was escalated up to a maximum dose of 3.0 mg QD. Participants either continued setmelanotide treatment by enrolling in an extension study (RM-493-022; NCT03651765) immediately following the last dose in this study or if the extension study was not open at the current clinic site, participants continued treatment in the current study for up to 1 year, resulting in treatment duration of up to 16 months.
Drug: Setmelanotide
RM-493 QD SC injection
Also known as: RM-493
Number of Participants With ≥ 5% Reduction in Body Weight From Baseline After 3 Months of Setmelanotide Treatment
Time frame: Baseline to Month 3
Number of Participants With Treatment-Emergent Adverse Events (TEAEs)
An adverse event (AE) was any untoward medical occurrence associated with the use of a drug in humans, whether or not considered drug-related. An AE (also referred to as an adverse experience) could be any unfavorable and unintended sign (e.g., an abnormal laboratory finding), symptom, or disease temporally associated with the use of a drug, without any judgment about causality. TEAEs were defined as AEs reported after dosing on Day 1.
Time frame: From first dose up to Month 16
Change From Baseline in Body Weight After 3 Months of Setmelanotide Treatment
Time frame: Baseline, Month 3
Percent Change From Baseline in Body Weight After 3 Months of Setmelanotide Treatment
Time frame: Baseline, Month 3
Change From Baseline in Daily Hunger Questionnaire Scores After 3 Months of Setmelanotide Treatment in Participants Aged ≥ 12 Years
The mean change in daily hunger questionnaire scores for participants ≥ 12 years of age with obesity in treatment with setmelanotide was evaluated. On the Daily Hunger Questionnaire, each of the 3 items (average hunger in the last 24 hours, most/worst hunger in the last 24 hours, and morning hunger) was assessed daily and scored separately using a numeric rating score for each from 0 to 10, with 0 = not hungry at all and 10 = hungriest possible.
Time frame: Baseline, Month 3
Change From Baseline in Daily Hunger Questionnaire Scores After 3 Months of Setmelanotide Treatment in Participants Aged < 12 Years
The mean change in daily hunger questionnaire scores for participants \< 12 years of age with obesity in treatment with setmelanotide was evaluated. Hunger was assessed daily using a Daily Hunger Questionnaire with a pictorial (smiley face) version of the Likert rating scale with scores ranged from 0 to 4, with 0 = not hungry at all and 4 = hungriest possible.
Time frame: Baseline, Month 3
Number of Participants With Shifts From Baseline in Global Hunger Questionnaire Scores After 3 Months of Setmelanotide Treatment in Participants Aged ≥ 12 Years
For participants ≥ 12 years of age, the following question was asked using the Global Hunger Questionnaire: Overall, how would you rate the hunger you experience now? Possible responses were: No hunger; Mild hunger; Moderate hunger; Severe hunger; and Not answered.
Time frame: Baseline, Month 3
Number of Participants With Shifts From Baseline in Global Hunger Questionnaire Scores After 3 Months of Setmelanotide Treatment in Participants Aged < 12 Years
For participants \< 12 years of age, the following question was asked to parents or caregivers of participants using the Global Hunger Questionnaire: How hungry is your child acting now? Possible responses were: Not hungry at all; A little hungry; Moderately hungry; Extremely hungry; and Not answered.
Time frame: Baseline, Month 3
Percent Change From Baseline in Waist Circumference After 3 Months of Setmelanotide Treatment
Waist circumference (cm) was measured according to the National Heart, Lung, and Blood Institute (NHLBI) criteria. All measurements were single measures. Waist circumference was measured when participants were in fasting condition and at approximately the same time at each visit.
Time frame: Baseline, Month 3
Of the 218 participants screened, 213 participants were enrolled in the study.
| Milestone | 16p11.2 Cohort | AS Cohort | BBS Cohort | MC4R Cohort | POMC/PCSK1/LEPR Heterozygous Cohort | POMC/PCSK1/LEPR Composite Heterozygous Cohort | POMC/PCSK1/LEPR Compound Heterozygous Cohort | SH2B1 Cohort | SMS Cohort | SRC1 Cohort |
|---|---|---|---|---|---|---|---|---|---|---|
| Started | 19 | 4 | 10 | 49 | 33 | 5 | 27 | 22 | 12 | 32 |
| Completed | 19 | 2 | 7 | 37 | 22 | 2 | 20 | 13 | 9 | 22 |
| Not completed | 0 | 2 | 3 | 12 | 11 | 3 | 7 | 9 | 3 | 10 |
| Withdrew: Withdrawal by subject | 0 | 2 | 0 | 5 | 6 | 2 | 3 | 1 | 0 | 4 |
| Withdrew: Withdrawal by parent/guardian | 0 | 0 | 1 | 1 | 0 | 0 | 0 | 0 | 1 | 1 |
| Withdrew: Other | 0 | 0 | 2 | 0 | 2 | 0 | 0 | 0 | 1 | 0 |
| Withdrew: Adverse event | 0 | 0 | 0 | 3 | 2 | 1 | 3 | 8 | 0 | 2 |
| Withdrew: Death | 0 | 0 | 0 | 1 | 0 | 0 | 0 | 0 | 0 | 0 |
| Withdrew: Lack of efficacy | 0 | 0 | 0 | 1 | 0 | 0 | 0 | 0 | 0 | 0 |
| Withdrew: Lost to follow-up | 0 | 0 | 0 | 1 | 0 | 0 | 1 | 0 | 0 | 2 |
| Withdrew: Non-compliance with study drug | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 0 |
| Withdrew: Physician decision | 0 | 0 | 0 | 0 | 1 | 0 | 0 | 0 | 0 | 0 |
| Withdrew: Protocol violation | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 |
| Participants | 16p11.2 Cohort | AS Cohort | BBS Cohort | MC4R Cohort | POMC/PCSK1/LEPR Heterozygous Cohort | POMC/PCSK1/LEPR Composite Heterozygous Cohort | POMC/PCSK1/LEPR Compound Heterozygous Cohort | SH2B1 Cohort | SMS Cohort | SRC1 Cohort |
|---|---|---|---|---|---|---|---|---|---|---|
| Number of Participants With ≥ 5% Reduction in Body Weight From Baseline After 3 Months of Setmelanotide Treatment | 6 | 3 | 7 | 7 | 10 | 0 | 14 | 8 | 1 | 9 |
An adverse event (AE) was any untoward medical occurrence associated with the use of a drug in humans, whether or not considered drug-related. An AE (also referred to as an adverse experience) could be any unfavorable and unintended sign (e.g., an abnormal laboratory finding), symptom, or disease temporally associated with the use of a drug, without any judgment about causality. TEAEs were defined as AEs reported after dosing on Day 1.
| Participants | 16p11.2 Cohort | AS Cohort | BBS Cohort | MC4R Cohort | POMC/PCSK1/LEPR Heterozygous Cohort | POMC/PCSK1/LEPR Composite Heterozygous Cohort | POMC/PCSK1/LEPR Compound Heterozygous Cohort | SH2B1 Cohort | SMS Cohort | SRC1 Cohort |
|---|---|---|---|---|---|---|---|---|---|---|
| Number of Participants With Treatment-Emergent Adverse Events (TEAEs) | 19 | 4 | 10 | 49 | 33 | 5 | 27 | 21 | 12 | 29 |
| kg | 16p11.2 Cohort | AS Cohort | BBS Cohort | MC4R Cohort | POMC/PCSK1/LEPR Heterozygous Cohort | POMC/PCSK1/LEPR Composite Heterozygous Cohort | POMC/PCSK1/LEPR Compound Heterozygous Cohort | SH2B1 Cohort | SMS Cohort | SRC1 Cohort |
|---|---|---|---|---|---|---|---|---|---|---|
| Change From Baseline in Body Weight After 3 Months of Setmelanotide Treatment | -2.58 ± 4.886 | -5.16 ± 3.860 | -4.61 ± 7.771 | -1.26 ± 4.851 | -4.74 ± 7.689 | -0.11 ± 2.432 | -7.24 ± 6.657 | -3.98 ± 5.164 | -0.14 ± 2.805 | -3.96 ± 4.370 |
| percent change | 16p11.2 Cohort | AS Cohort | BBS Cohort | MC4R Cohort | POMC/PCSK1/LEPR Heterozygous Cohort | POMC/PCSK1/LEPR Composite Heterozygous Cohort | POMC/PCSK1/LEPR Compound Heterozygous Cohort | SH2B1 Cohort | SMS Cohort | SRC1 Cohort |
|---|---|---|---|---|---|---|---|---|---|---|
| Percent Change From Baseline in Body Weight After 3 Months of Setmelanotide Treatment | -2.19 ± 3.685 | -6.38 ± 5.043 | -4.19 ± 5.579 | -0.75 ± 4.291 | -3.50 ± 5.817 | -0.31 ± 1.772 | -5.57 ± 5.170 | -2.92 ± 3.834 | -0.00 ± 3.651 | -3.34 ± 3.607 |
The mean change in daily hunger questionnaire scores for participants ≥ 12 years of age with obesity in treatment with setmelanotide was evaluated. On the Daily Hunger Questionnaire, each of the 3 items (average hunger in the last 24 hours, most/worst hunger in the last 24 hours, and morning hunger) was assessed daily and scored separately using a numeric rating score for each from 0 to 10, with 0 = not hungry at all and 10 = hungriest possible.
| units on a scale | 16p11.2 Cohort | AS Cohort | BBS Cohort | MC4R Cohort | POMC/PCSK1/LEPR Heterozygous Cohort | POMC/PCSK1/LEPR Composite Heterozygous Cohort | POMC/PCSK1/LEPR Compound Heterozygous Cohort | SH2B1 Cohort | SMS Cohort | SRC1 Cohort |
|---|---|---|---|---|---|---|---|---|---|---|
| Baseline: Hunger Score on Average Last 24 hours | 6.11 ± 2.102 | 5.07 ± 1.860 | 6.37 ± 1.719 | 5.74 ± 1.915 | 5.73 ± 2.178 | 8.07 ± 1.348 | 6.32 ± 2.062 | 6.66 ± 1.966 | — | 6.04 ± 2.049 |
| Change at Month 3: Hunger Score on Average Last 24 hours | -2.57 ± 2.602 | -1.23 ± 2.739 | -3.21 ± 2.858 | -2.50 ± 2.278 | -2.71 ± 1.946 | -3.21 ± 2.525 | -3.12 ± 1.911 | -2.78 ± 2.639 | — | -2.47 ± 2.003 |
| Baseline: Hunger Score at Most Hungry Last 24 hours | 7.23 ± 2.168 | 6.06 ± 2.185 | 7.50 ± 1.407 | 6.84 ± 1.866 | 6.95 ± 2.281 | 8.82 ± 0.936 | 7.45 ± 2.376 | 7.42 ± 1.870 | — | 6.91 ± 1.952 |
| Change at Month 3: Hunger Score at Most Hungry Last 24 hours | -2.85 ± 2.561 | -2.27 ± 3.656 | -4.00 ± 2.717 | -2.91 ± 2.155 | -3.00 ± 2.264 | -4.07 ± 2.929 | -3.70 ± 2.501 | -2.68 ± 2.915 | — | -2.67 ± 2.241 |
| Baseline: Hunger Score in Morning | 5.24 ± 2.508 | 4.98 ± 3.187 | 5.31 ± 2.705 | 3.99 ± 2.805 | 3.89 ± 2.589 | 7.04 ± 2.437 | 5.14 ± 2.537 | 4.96 ± 2.829 | — | 4.60 ± 2.924 |
| Change at Month 3: Hunger Score in Morning | -2.34 ± 3.390 | -3.90 ± 4.195 | -3.14 ± 3.173 | -2.14 ± 2.914 | -2.85 ± 2.084 | -2.36 ± 1.111 | -3.15 ± 1.781 | -3.09 ± 1.961 | — | -1.88 ± 1.942 |
The mean change in daily hunger questionnaire scores for participants \< 12 years of age with obesity in treatment with setmelanotide was evaluated. Hunger was assessed daily using a Daily Hunger Questionnaire with a pictorial (smiley face) version of the Likert rating scale with scores ranged from 0 to 4, with 0 = not hungry at all and 4 = hungriest possible.
| units on a scale | 16p11.2 Cohort | AS Cohort | BBS Cohort | MC4R Cohort | POMC/PCSK1/LEPR Heterozygous Cohort | POMC/PCSK1/LEPR Composite Heterozygous Cohort | POMC/PCSK1/LEPR Compound Heterozygous Cohort | SH2B1 Cohort | SMS Cohort | SRC1 Cohort |
|---|---|---|---|---|---|---|---|---|---|---|
| Baseline: Hunger Right Now | 2.32 ± 0.741 | — | — | 2.02 ± 1.300 | — | — | 2.17 ± 1.443 | 1.87 ± 0.125 | — | — |
| Change at Month 3: Hunger Right Now | -1.57 ± 0.261 | — | — | -0.72 ± 1.346 | — | — | -1.55 ± 0.910 | -1.44 ± 0.387 | — | — |
For participants ≥ 12 years of age, the following question was asked using the Global Hunger Questionnaire: Overall, how would you rate the hunger you experience now? Possible responses were: No hunger; Mild hunger; Moderate hunger; Severe hunger; and Not answered.
| participants | 16p11.2 Cohort | AS Cohort | BBS Cohort | MC4R Cohort | POMC/PCSK1/LEPR Heterozygous Cohort | POMC/PCSK1/LEPR Composite Heterozygous Cohort | POMC/PCSK1/LEPR Compound Heterozygous Cohort | SH2B1 Cohort | SMS Cohort | SRC1 Cohort |
|---|---|---|---|---|---|---|---|---|---|---|
| No hunger (Baseline) - No hunger (Month 3) | 2 | 0 | 0 | 1 | 2 | 0 | 0 | 0 | 0 | 1 |
| No hunger (Baseline) - Mild hunger (Month 3) | 0 | 0 | 1 | 2 | 0 | 0 | 0 | 0 | 0 | 1 |
| No hunger (Baseline) - Moderate hunger (Month 3) | 0 | 0 | 0 | 1 | 1 | 0 | 0 | 0 | 0 | 1 |
| No hunger (Baseline) - Severe hunger (Month 3) | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| No hunger (Baseline) - Not answered (Month 3) | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Mild hunger (Baseline) - No hunger (Month 3) | 0 | 0 | 0 | 2 | 3 | 0 | 2 | 3 | 1 | 4 |
| Mild hunger (Baseline) - Mild hunger (Month 3) | 1 | 2 | 2 | 5 | 0 | 0 | 4 | 0 | 1 | 5 |
| Mild hunger (Baseline) - Moderate hunger (Month 3) | 1 | 0 | 0 | 2 | 0 | 0 | 0 | 0 | 1 | 1 |
| Mild hunger (Baseline) - Severe hunger (Month 3) | 0 | 0 | 0 | 0 | 1 | 0 | 0 | 0 | 0 | 0 |
| Mild hunger (Baseline) - Not answered (Month 3) | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Moderate hunger (Baseline) - No hunger (Month 3) | 2 | 0 | 0 | 1 | 0 | 0 | 1 | 1 | 1 | 0 |
| Moderate hunger (Baseline) - Mild hunger (Month 3) | 4 | 0 | 4 | 4 | 5 | 1 | 4 | 3 | 1 | 3 |
| Moderate hunger (Baseline) - Moderate hunger (Month 3) | 2 | 0 | 0 | 2 | 1 | 0 | 0 | 0 | 0 | 2 |
| Moderate hunger (Baseline) - Severe hunger (Month 3) | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Moderate hunger (Baseline) - Not answered (Month 3) | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Severe hunger (Baseline) - No hunger (Month 3) | 1 | 0 | 1 | 1 | 1 | 0 | 2 | 1 | 0 | 0 |
| Severe hunger (Baseline) - Mild hunger (Month 3) | 1 | 1 | 0 | 5 | 1 | 0 | 1 | 2 | 0 | 2 |
| Severe hunger (Baseline) - Moderate hunger (Month 3) | 1 | 0 | 0 | 1 | 1 | 0 | 1 | 0 | 2 | 0 |
| Severe hunger (Baseline) - Severe hunger (Month 3) | 0 | 0 | 0 | 0 | 0 | 0 | 2 | 0 | 1 | 0 |
| Severe hunger (Baseline) - Not answered (Month 3) | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Not answered (Baseline) - No hunger (Month 3) | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Not answered (Baseline) - Mild hunger (Month 3) | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Not answered (Baseline) - Moderate hunger (Month 3) | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Not answered (Baseline) - Severe hunger (Month 3) | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Not answered (Baseline) - Not answered (Month 3) | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
For participants \< 12 years of age, the following question was asked to parents or caregivers of participants using the Global Hunger Questionnaire: How hungry is your child acting now? Possible responses were: Not hungry at all; A little hungry; Moderately hungry; Extremely hungry; and Not answered.
| participants | 16p11.2 Cohort | AS Cohort | BBS Cohort | MC4R Cohort | POMC/PCSK1/LEPR Heterozygous Cohort | POMC/PCSK1/LEPR Composite Heterozygous Cohort | POMC/PCSK1/LEPR Compound Heterozygous Cohort | SH2B1 Cohort | SMS Cohort | SRC1 Cohort |
|---|---|---|---|---|---|---|---|---|---|---|
| Not hungry at all (Baseline) - Not hungry at all (Month 3) | 0 | — | — | 1 | — | 0 | 0 | 0 | — | 0 |
| Not hungry at all (Baseline) - A little hungry (Month 3) | 0 | — | — | 0 | — | 0 | 0 | 0 | — | 0 |
| Not hungry at all (Baseline) - Moderately hungry (Month 3) | 0 | — | — | 0 | — | 0 | 0 | 0 | — | 0 |
| Not hungry at all (Baseline) - Extremely hungry (Month 3) | 0 | — | — | 1 | — | 0 | 0 | 0 | — | 0 |
| Not hungry at all (Baseline) - Not answered (Month 3) | 0 | — | — | 0 | — | 0 | 0 | 0 | — | 0 |
| A little hungry (Baseline) - Not hungry at all (Month 3) | 0 | — | — | 0 | — | 0 | 0 | 0 | — | 0 |
| A little hungry (Baseline) - A little hungry (Month 3) | 1 | — | — | 1 | — | 1 | 2 | 1 | — | 0 |
| A little hungry (Baseline) - Moderately hungry (Month 3) | 0 | — | — | 1 | — | 0 | 0 | 0 | — | 0 |
| A little hungry (Baseline) - Extremely hungry (Month 3) | 0 | — | — | 0 | — | 0 | 0 | 0 | — | 0 |
| A little hungry (Baseline) - Not answered (Month 3) | 0 | — | — | 0 | — | 0 | 0 | 0 | — | 0 |
| Moderately hungry (Baseline) - Not hungry at all (Month 3) | 0 | — | — | 0 | — | 0 | 0 | 0 | — | 0 |
| Moderately hungry (Baseline) - A little hungry (Month 3) | 0 | — | — | 0 | — | 0 | 0 | 0 | — | 0 |
| Moderately hungry (Baseline) - Moderately hungry (Month 3) | 0 | — | — | 0 | — | 0 | 0 | 1 | — | 0 |
| Moderately hungry (Baseline) - Extremely hungry (Month 3) | 0 | — | — | 0 | — | 0 | 0 | 0 | — | 0 |
| Moderately hungry (Baseline) - Not answered (Month 3) | 0 | — | — | 0 | — | 0 | 0 | 0 | — | 0 |
| Extremely hungry (Baseline) - Not hungry at all (Month 3) | 0 | — | — | 0 | — | 0 | 0 | 0 | — | 1 |
| Extremely hungry (Baseline) - A little hungry (Month 3) | 1 | — | — | 2 | — | 0 | 0 | 0 | — | 1 |
| Extremely hungry (Baseline) - Moderately hungry (Month 3) | 0 | — | — | 0 | — | 0 | 0 | 0 | — | 0 |
| Extremely hungry (Baseline) - Extremely hungry (Month 3) | 0 | — | — | 1 | — | 0 | 0 | 0 | — | 0 |
| Extremely hungry (Baseline) - Not answered (Month 3) | 0 | — | — | 0 | — | 0 | 0 | 0 | — | 0 |
| Not answered (Baseline) - Not hungry at all (Month 3) | 0 | — | — | 0 | — | 0 | 0 | 0 | — | 0 |
| Not answered (Baseline) - A little hungry (Month 3) | 0 | — | — | 0 | — | 0 | 0 | 0 | — | 0 |
| Not answered (Baseline) - Moderately hungry (Month 3) | 0 | — | — | 0 | — | 0 | 0 | 0 | — | 0 |
| Not answered (Baseline) - Extremely hungry (Month 3) | 0 | — | — | 0 | — | 0 | 0 | 0 | — | 0 |
| Not answered (Baseline) - Not answered (Month 3) | 0 | — | — | 0 | — | 0 | 0 | 0 | — | 0 |
Waist circumference (cm) was measured according to the National Heart, Lung, and Blood Institute (NHLBI) criteria. All measurements were single measures. Waist circumference was measured when participants were in fasting condition and at approximately the same time at each visit.
| percent change | 16p11.2 Cohort | AS Cohort | BBS Cohort | MC4R Cohort | POMC/PCSK1/LEPR Heterozygous Cohort | POMC/PCSK1/LEPR Composite Heterozygous Cohort | POMC/PCSK1/LEPR Compound Heterozygous Cohort | SH2B1 Cohort | SMS Cohort | SRC1 Cohort |
|---|---|---|---|---|---|---|---|---|---|---|
| Percent Change From Baseline in Waist Circumference After 3 Months of Setmelanotide Treatment | -1.00 ± 6.250 | -6.60 ± 6.828 | -4.92 ± 7.191 | -0.61 ± 11.311 | -1.09 ± 8.250 | 5.11 ± 8.412 | -5.59 ± 6.554 | -4.91 ± 8.495 | -3.83 ± 8.543 | -2.88 ± 4.632 |
Collected over From first dose up to Month 16. Non-serious events are listed at a 0% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| 16p11.2 Cohort | 0/19 (0%) | 1/19 (5.3%) | 19/19 (100%) |
| AS Cohort | 0/4 (0%) | 0/4 (0%) | 4/4 (100%) |
| BBS Cohort | 0/10 (0%) | 1/10 (10%) | 10/10 (100%) |
| MC4R Cohort | 1/49 (2%) | 1/49 (2%) | 48/49 (98%) |
| POMC/PCSK1/LEPR Heterozygous Cohort | 0/33 (0%) | 1/33 (3%) | 33/33 (100%) |
| POMC/PCSK1/LEPR Composite Heterozygous Cohort | 0/5 (0%) | 1/5 (20%) | 5/5 (100%) |
| POMC/PCSK1/LEPR Compound Heterozygous Cohort | 0/27 (0%) | 2/27 (7.4%) | 27/27 (100%) |
| SH2B1 Cohort | 0/22 (0%) | 0/22 (0%) | 21/22 (95.5%) |
| SMS Cohort | 0/12 (0%) | 0/12 (0%) | 12/12 (100%) |
| SRC1 Cohort | 0/32 (0%) | 0/32 (0%) | 29/32 (90.6%) |
| Event | 16p11.2 Cohort | AS Cohort | BBS Cohort | MC4R Cohort | POMC/PCSK1/LEPR Heterozygous Cohort | POMC/PCSK1/LEPR Composite Heterozygous Cohort | POMC/PCSK1/LEPR Compound Heterozygous Cohort | SH2B1 Cohort | SMS Cohort | SRC1 Cohort |
|---|---|---|---|---|---|---|---|---|---|---|
| HypersensitivityImmune system disorders | 0/19 | 0/4 | 0/10 | 0/49 | 0/33 | 1/5 | 0/27 | 0/22 | 0/12 | 0/32 |
| Rotavirus InfectionInfections and infestations | 0/19 | 0/4 | 1/10 | 0/49 | 0/33 | 0/5 | 0/27 | 0/22 | 0/12 | 0/32 |
| Melanocytic NaevusNeoplasms benign, malignant and unspecified (incl cysts and polyps) | 1/19 | 0/4 | 0/10 | 0/49 | 0/33 | 0/5 | 0/27 | 0/22 | 0/12 | 0/32 |
| DiverticulitisInfections and infestations | 0/19 | 0/4 | 0/10 | 0/49 | 0/33 | 0/5 | 1/27 | 0/22 | 0/12 | 0/32 |
| Typical Aura Without HeadacheNeoplasms benign, malignant and unspecified (incl cysts and polyps) | 0/19 | 0/4 | 0/10 | 0/49 | 0/33 | 0/5 | 1/27 | 0/22 | 0/12 | 0/32 |
| Acute Myocardial InfarctionCardiac disorders | 0/19 | 0/4 | 0/10 | 1/49 | 1/33 | 0/5 | 0/27 | 0/22 | 0/12 | 0/32 |
| Gastrointestinal HaemorrhageGastrointestinal disorders | 0/19 | 0/4 | 0/10 | 0/49 | 1/33 | 0/5 | 0/27 | 0/22 | 0/12 | 0/32 |
| Event | 16p11.2 Cohort | AS Cohort | BBS Cohort | MC4R Cohort | POMC/PCSK1/LEPR Heterozygous Cohort | POMC/PCSK1/LEPR Composite Heterozygous Cohort | POMC/PCSK1/LEPR Compound Heterozygous Cohort | SH2B1 Cohort | SMS Cohort | SRC1 Cohort |
|---|---|---|---|---|---|---|---|---|---|---|
| Injection Site PruritusGeneral disorders | 5/19 | 2/4 | 9/10 | 3/49 | 8/33 | 1/5 | 4/27 | 2/22 | 1/12 | 0/32 |
| Skin HyperpigmentationSkin and subcutaneous tissue disorders | 17/19 | 3/4 | 8/10 | 40/49 | 19/33 | 3/5 | 21/27 | 16/22 | 10/12 | 23/32 |
| NauseaGastrointestinal disorders | 9/19 | 1/4 | 3/10 | 12/49 | 14/33 | 4/5 | 13/27 | 13/22 | 2/12 | 11/32 |
| Injection Site OedemaGeneral disorders | 0/19 | 0/4 | 7/10 | 0/49 | 2/33 | 1/5 | 0/27 | 0/22 | 1/12 | 0/32 |
| Injection Site ErythemaGeneral disorders | 4/19 | 0/4 | 6/10 | 4/49 | 8/33 | 2/5 | 4/27 | 1/22 | 0/12 | 0/32 |
| Injection Site IndurationGeneral disorders | 2/19 | 0/4 | 5/10 | 3/49 | 3/33 | 0/5 | 0/27 | 0/22 | 1/12 | 0/32 |
| Viral Upper Respiratory Tract InfectionInfections and infestations | 0/19 | 2/4 | 0/10 | 0/49 | 0/33 | 0/5 | 0/27 | 0/22 | 0/12 | 0/32 |
| HeadacheNervous system disorders | 9/19 | 0/4 | 1/10 | 10/49 | 8/33 | 1/5 | 13/27 | 10/22 | 1/12 | 7/32 |
| VomitingGastrointestinal disorders | 1/19 | 0/4 | 2/10 | 7/49 | 4/33 | 2/5 | 6/27 | 6/22 | 0/12 | 4/32 |
| InsomniaPsychiatric disorders | 3/19 | 0/4 | 0/10 | 2/49 | 3/33 | 2/5 | 1/27 | 1/22 | 0/12 | 1/32 |
The Full Analysis Set (FAS) included all participants who received at least 1 dose of study drug and had baseline weight data.
| Age, Continuous(years) | 16p11.2 Cohort | AS Cohort | BBS Cohort | MC4R Cohort | POMC/PCSK1/LEPR Heterozygous Cohort | POMC/PCSK1/LEPR Composite Heterozygous Cohort | POMC/PCSK1/LEPR Compound Heterozygous Cohort | SH2B1 Cohort | SMS Cohort | SRC1 Cohort | Total |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Mean | 21.4 ± 14.58 | 16.0 ± 3.74 | 22.5 ± 14.71 | 22.4 ± 15.28 | 36.1 ± 17.23 | 40.4 ± 19.62 | 30.7 ± 20.16 | 33.6 ± 17.88 | 19.4 ± 8.10 | 31.3 ± 17.13 | 28.1 ± 17.30 |
| Sex: Female, Male(Participants) | 16p11.2 Cohort | AS Cohort | BBS Cohort | MC4R Cohort | POMC/PCSK1/LEPR Heterozygous Cohort | POMC/PCSK1/LEPR Composite Heterozygous Cohort | POMC/PCSK1/LEPR Compound Heterozygous Cohort | SH2B1 Cohort | SMS Cohort | SRC1 Cohort | Total |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Female | 13 | 3 | 6 | 27 | 22 | 4 | 18 | 15 | 10 | 25 | 143 |
| Male | 6 | 1 | 4 | 22 | 11 | 1 | 9 | 7 | 2 | 7 | 70 |
| Ethnicity (NIH/OMB)(Participants) | 16p11.2 Cohort | AS Cohort | BBS Cohort | MC4R Cohort | POMC/PCSK1/LEPR Heterozygous Cohort | POMC/PCSK1/LEPR Composite Heterozygous Cohort | POMC/PCSK1/LEPR Compound Heterozygous Cohort | SH2B1 Cohort | SMS Cohort | SRC1 Cohort | Total |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Hispanic or Latino | 1 | 0 | 1 | 3 | 2 | 0 | 0 | 2 | 2 | 3 | 14 |
| Not Hispanic or Latino | 13 | 4 | 8 | 40 | 31 | 5 | 25 | 19 | 10 | 29 | 184 |
| Unknown or Not Reported | 5 | 0 | 1 | 6 | 0 | 0 | 2 | 1 | 0 | 0 | 15 |
| Race (NIH/OMB)(Participants) | 16p11.2 Cohort | AS Cohort | BBS Cohort | MC4R Cohort | POMC/PCSK1/LEPR Heterozygous Cohort | POMC/PCSK1/LEPR Composite Heterozygous Cohort | POMC/PCSK1/LEPR Compound Heterozygous Cohort | SH2B1 Cohort | SMS Cohort | SRC1 Cohort | Total |
|---|---|---|---|---|---|---|---|---|---|---|---|
| American Indian or Alaska Native | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 0 | 0 | 1 |
| Asian | 0 | 1 | 0 | 0 | 0 | 0 | 1 | 1 | 0 | 0 | 3 |
| Native Hawaiian or Other Pacific Islander | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Black or African American | 0 | 1 | 1 | 3 | 5 | 1 | 0 | 5 | 1 | 6 | 23 |
| White | 15 | 2 | 9 | 38 | 28 | 4 | 23 | 13 | 10 | 24 | 166 |
| More than one race | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Unknown or Not Reported | 4 | 0 | 0 | 8 | 0 | 0 | 3 | 2 | 1 | 2 | 20 |
| Body Weight(kilograms (kg)) | 16p11.2 Cohort | AS Cohort | BBS Cohort | MC4R Cohort | POMC/PCSK1/LEPR Heterozygous Cohort | POMC/PCSK1/LEPR Composite Heterozygous Cohort | POMC/PCSK1/LEPR Compound Heterozygous Cohort | SH2B1 Cohort | SMS Cohort | SRC1 Cohort | Total |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Mean | 113.62 ± 38.489 | 87.28 ± 16.360 | 128.04 ± 28.631 | 117.87 ± 32.339 | 143.04 ± 30.492 | 139.05 ± 30.957 | 122.08 ± 43.315 | 129.06 ± 39.480 | 92.48 ± 24.556 | 124.07 ± 33.717 | 122.98 ± 36.142 |
| Waist Circumference(centimeters (cm)) | 16p11.2 Cohort | AS Cohort | BBS Cohort | MC4R Cohort | POMC/PCSK1/LEPR Heterozygous Cohort | POMC/PCSK1/LEPR Composite Heterozygous Cohort | POMC/PCSK1/LEPR Compound Heterozygous Cohort | SH2B1 Cohort | SMS Cohort | SRC1 Cohort | Total |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Mean | 116.84 ± 22.179 | 109.75 ± 14.523 | 126.20 ± 19.344 | 122.52 ± 19.697 | 137.95 ± 18.529 | 134.00 ± 19.038 | 128.52 ± 28.772 | 130.28 ± 23.029 | 110.14 ± 11.807 | 123.10 ± 21.101 | 125.63 ± 22.162 |
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: No
Ran from Feb 2017 to primary completion in Mar 2022, 60 months.
Results were first posted in Aug 2023, 1 year 5 months after primary completion.
Of 176 industry-sponsored phase 2 interventional studies under Obesity, half reached primary completion within 12 months of starting (the median), counting those still running; a quarter within 8 and three quarters within 18. This study's 60 months is above that.
Counting every sponsor, half of 307 studies reached it within 16 months; a quarter within 10 and three quarters within 35.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Jul 2023. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Setmelanotide
Rhythm Pharmaceuticals, Inc. →